Rania Barlas Khan, MD
Family Practice · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Offices
- 2
Offices
2 locations · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center · Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Khan’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A160010 · Current
Licensed to practise in California · since 2018 · expires 2028-12-31 · Emory University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Medicaid work
$407,677 in 2024
Medicaid paid $407,677 for 4,895 billed services this clinician did in 2024, up to 133 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 639 | $405,805 |
| Short return visit (20+ min) | 879 | $1,100 |
| Return visit (30+ min) | 252 | $377 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 16 | $213 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 62 | $86 |
| Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 57 | $66 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 123 | $29 |
| Pain severity quantified; pain present (COA) (ONC) | 70 | $0 |
| Pain severity quantified; no pain present (COA) (ONC) | 198 | $0 |
| Medication list documented in medical record (COA) | 345 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 684 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 221 | $0 |
| 2024 | 4,895 | 16 | 133 | $407,677 |
| 2023 | 5,687 | 14 | 142 | $766,294 |
| 2022 | 4,764 | 12 | 156 | $695,600 |
| 2021 | 5,558 | 15 | 196 | $802,663 |
| 2020 | 3,604 | 7 | 207 | $335,788 |
| 2019 | 474 | 2 | 79 | $47,341 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 1,244 | $759,586 |
| Short return visit (20+ min) | 2,033 | $5,821 |
| Return visit (30+ min) | 216 | $430 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 145 | $156 |
| Hemoglobin A1C level | 12 | $132 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 215 | $107 |
| Payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (rhc) or federally qualified health center (fqhc) practitioner and rhc or fqhc patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an rhc or fqhc practitioner, occurring in lieu of an office visit; rhc or fqhc only | 12 | $62 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 164 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 556 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 132 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 149 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 584 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 1,153 | $688,759 |
| Short return visit (20+ min) | 1,835 | $4,636 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose | 23 | $920 |
| Return visit (30+ min) | 212 | $765 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose | 13 | $520 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 181 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 522 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 60 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 78 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 559 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 108 | $0 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 20 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 1,612 | $796,559 |
| Short return visit (20+ min) | 2,158 | $2,865 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose | 34 | $1,360 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose | 27 | $1,080 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose | 12 | $480 |
| Short return visit | 443 | $274 |
| Return visit (30+ min) | 72 | $41 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 22 | $5 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 93 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 375 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 97 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 84 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 1,455 | $333,701 |
| Payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (rhc) or federally qualified health center (fqhc) practitioner and rhc or fqhc patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an rhc or fqhc practitioner, occurring in lieu of an office visit; rhc or fqhc only | 142 | $952 |
| Short return visit (20+ min) | 1,729 | $935 |
| Short return visit | 108 | $199 |
| Return visit (30+ min) | 120 | $0 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion | 18 | $0 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion | 32 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 175 | $46,493 |
| Short return visit (20+ min) | 299 | $848 |
Drugs they prescribed that Part D paid
$115,919
Pharmacies billed $115,919 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 8% of their Part D prescriptions (76 of 1,009) in 2024. A higher opioid share than 9 in 10 peers; the typical family practice clinician is at 2%. Long-acting opioids: 72% of their opioid prescriptions.
807 generic and fewer than 11 brand-name prescriptions · $115,919 in drug cost · 11 antibiotic prescriptions · 11 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jardiance | 21 | $23,917 | $1,139 |
| Belbuca | 35 | $23,299 | $666 |
| Xarelto | 15 | $9,942 | $663 |
| Buprenorphine-Naloxone | 12 | $2,827 | $236 |
| Gabapentin | 46 | $780 | $17 |
See all 27 drugs
| Jardiance | 21 | $23,917 | $1,139 |
| Belbuca | 35 | $23,299 | $666 |
| Xarelto | 15 | $9,942 | $663 |
| Buprenorphine-Naloxone | 12 | $2,827 | $236 |
| Gabapentin | 46 | $780 | $17 |
| Albuterol Sulfate Hfa | 24 | $778 | $32 |
| Perphenazine | 11 | $374 | $34 |
| Atorvastatin | 70 | $360 | $5 |
| Metformin | 53 | $337 | $6 |
| Amlodipine Besylate | 34 | $294 | $9 |
| Tamsulosin | 27 | $290 | $11 |
| Hydrocodone-Acetaminophen | 15 | $267 | $18 |
| Levothyroxine | 25 | $185 | $7 |
| Simvastatin | 18 | $168 | $9 |
| Losartan | 28 | $161 | $6 |
| Lisinopril | 31 | $146 | $5 |
| Pravastatin | 12 | $120 | $10 |
| Finasteride | 13 | $119 | $9 |
| Pantoprazole | 12 | $118 | $10 |
| Triamcinolone Acetonide | 12 | $111 | $9 |
| Ketoconazole | 11 | $105 | $10 |
| Omeprazole | 18 | $105 | $6 |
| Fluticasone Propionate | 12 | $93 | $8 |
| Fluoxetine | 19 | $59 | $3 |
| Hydroxyzine | 13 | $44 | $3 |
| Hydrochlorothiazide | 17 | $35 | $2 |
| Ibuprofen | 12 | $33 | $3 |
Year by year
| 2024 | 1,009 | 143 | 8% (76) | None | $115,919 |
| 2023 | 1,310 | 168 | 10% (134) | None | $151,989 |
| 2022 | 1,550 | 221 | 9% (144) | None | $175,404 |
| 2021 | 1,233 | 172 | 10% (120) | None | $103,626 |
| 2020 | 668 | 131 | 12% (79) | None | $41,713 |
| 2019 | 463 | 84 | 5% (21) | 21% | $51,037 |
| 2018 | 349 | 67 | 6% (21) | 19% | $29,775 |
| 2017 | 193 | 43 | None | None | $8,752 |
| 2016 | 30 | 11 | 0% (0) | None | $420 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 42 drugs
| Belbuca | 31 | $21,274 | $686 |
| Jardiance | 11 | $16,263 | $1,478 |
| Suboxone | 12 | $10,476 | $873 |
| Nucynta | 11 | $10,301 | $936 |
| Xarelto | 13 | $7,590 | $584 |
| Buprenorphine-Naloxone | 28 | $5,702 | $204 |
| Gabapentin | 62 | $2,053 | $33 |
| Tamsulosin | 29 | $1,115 | $38 |
| Pregabalin | 19 | $1,093 | $58 |
| Albuterol Sulfate Hfa | 20 | $1,081 | $54 |
| Atorvastatin | 59 | $792 | $13 |
| Perphenazine | 14 | $664 | $47 |
| Hydrocodone-Acetaminophen | 32 | $661 | $21 |
| Celecoxib | 16 | $655 | $41 |
| Buprenorphine | 13 | $647 | $50 |
| Fluvoxamine Maleate | 12 | $603 | $50 |
| Losartan | 33 | $590 | $18 |
| Levothyroxine | 38 | $587 | $15 |
| Simvastatin | 15 | $533 | $36 |
| Diclofenac | 22 | $520 | $24 |
| Metformin | 35 | $505 | $14 |
| Hydroxyzine | 35 | $504 | $14 |
| Amlodipine Besylate | 56 | $489 | $9 |
| Omeprazole | 36 | $425 | $12 |
| Fluoxetine | 14 | $396 | $28 |
| Finasteride | 32 | $386 | $12 |
| Trazodone | 17 | $360 | $21 |
| Acetaminophen-Codeine | 16 | $279 | $17 |
| Cyclobenzaprine | 25 | $256 | $10 |
| Fluticasone Propionate | 21 | $250 | $12 |
| Metoprolol | 12 | $203 | $17 |
| Lisinopril | 45 | $196 | $4 |
| Ketoconazole | 13 | $195 | $15 |
| Nortriptyline | 16 | $194 | $12 |
| Allopurinol | 13 | $131 | $10 |
| Hydroxyzine Pamoate | 11 | $121 | $11 |
| Montelukast | 11 | $94 | $9 |
| Ibuprofen | 19 | $78 | $4 |
| Promethazine | 12 | $70 | $6 |
| Naproxen | 11 | $66 | $6 |
| Furosemide | 17 | $59 | $3 |
| Hydrochlorothiazide | 11 | $46 | $4 |
2022: 51 drugs
| Jardiance | 14 | $19,966 | $1,426 |
| Belbuca | 24 | $13,794 | $575 |
| Buprenorphine-Naloxone | 53 | $13,432 | $253 |
| Xarelto | 14 | $10,047 | $718 |
| Nucynta | 11 | $9,495 | $863 |
| Oxycontin | 12 | $7,750 | $646 |
| Xtampza Er | 14 | $7,737 | $553 |
| Butrans | 14 | $7,207 | $515 |
| Flovent Hfa | 15 | $4,068 | $271 |
| Arnuity Ellipta | 13 | $2,464 | $190 |
| Albuterol Sulfate Hfa | 22 | $1,557 | $71 |
| Gabapentin | 79 | $1,497 | $19 |
| Pregabalin | 20 | $875 | $44 |
| Celecoxib | 21 | $778 | $37 |
| Hydrocodone-Acetaminophen | 39 | $747 | $19 |
| Atorvastatin | 71 | $745 | $10 |
| Oxybutynin Chloride | 12 | $572 | $48 |
| Losartan | 61 | $488 | $8 |
| Diclofenac | 20 | $434 | $22 |
| Dicyclomine | 11 | $432 | $39 |
| Simvastatin | 18 | $375 | $21 |
| Levothyroxine | 25 | $372 | $15 |
| Cyclobenzaprine | 26 | $363 | $14 |
| Fluoxetine | 21 | $347 | $17 |
| Tamsulosin | 35 | $344 | $10 |
| Hydroxyzine | 23 | $309 | $13 |
| Acetaminophen-Codeine | 14 | $275 | $20 |
| Buspirone | 13 | $269 | $21 |
| Omeprazole | 33 | $260 | $8 |
| Alendronate | 13 | $259 | $20 |
| Trazodone | 16 | $259 | $16 |
| Metformin | 34 | $257 | $8 |
| Metoprolol | 12 | $226 | $19 |
| Ketoconazole | 14 | $222 | $16 |
| Fluticasone Propionate | 28 | $215 | $8 |
| Amlodipine Besylate | 42 | $207 | $5 |
| Lisinopril | 42 | $198 | $5 |
| Bupropion Hcl Sr | 15 | $194 | $13 |
| Glipizide | 18 | $177 | $10 |
| Finasteride | 21 | $143 | $7 |
| Isosorbide Mononitrate Er | 13 | $142 | $11 |
| Naproxen | 34 | $139 | $4 |
| Furosemide | 19 | $138 | $7 |
| Hydrochlorothiazide | 13 | $111 | $9 |
| Montelukast | 11 | $107 | $10 |
| Atenolol | 11 | $103 | $9 |
| Fosinopril | 17 | $103 | $6 |
| Benazepril | 12 | $93 | $8 |
| Topiramate | 13 | $93 | $7 |
| Promethazine | 11 | $73 | $7 |
| Ibuprofen | 17 | $69 | $4 |
2021: 34 drugs
| Belbuca | 20 | $9,439 | $472 |
| Nucynta | 11 | $8,084 | $735 |
| Buprenorphine-Naloxone | 35 | $7,123 | $204 |
| Xtampza Er | 12 | $7,030 | $586 |
| Gabapentin | 61 | $879 | $14 |
| Celecoxib | 18 | $867 | $48 |
| Atorvastatin | 77 | $804 | $10 |
| Albuterol Sulfate Hfa | 13 | $789 | $61 |
| Pregabalin | 19 | $783 | $41 |
| Hydrocodone-Acetaminophen | 38 | $574 | $15 |
| Acetaminophen-Codeine | 12 | $376 | $31 |
| Metoprolol | 25 | $304 | $12 |
| Trazodone | 39 | $295 | $8 |
| Levothyroxine | 15 | $255 | $17 |
| Losartan | 32 | $241 | $8 |
| Buspirone | 16 | $210 | $13 |
| Lisinopril | 37 | $206 | $6 |
| Bupropion Hcl Sr | 14 | $198 | $14 |
| Amlodipine Besylate | 36 | $182 | $5 |
| Simvastatin | 13 | $181 | $14 |
| Cyclobenzaprine | 27 | $179 | $7 |
| Metformin | 39 | $147 | $4 |
| Fluticasone Propionate | 14 | $120 | $9 |
| Tamsulosin | 35 | $113 | $3 |
| Hydroxyzine | 18 | $111 | $6 |
| Famotidine | 11 | $110 | $10 |
| Lamotrigine | 12 | $107 | $9 |
| Hydroxyzine Pamoate | 18 | $102 | $6 |
| Furosemide | 17 | $100 | $6 |
| Fosinopril | 14 | $84 | $6 |
| Ibuprofen | 28 | $80 | $3 |
| Omeprazole | 13 | $72 | $6 |
| Glipizide | 18 | $67 | $4 |
| Fluoxetine | 12 | $60 | $5 |
2020: 19 drugs
| Buprenorphine-Naloxone | 36 | $6,719 | $187 |
| Belbuca | 16 | $6,076 | $380 |
| Ventolin Hfa | 17 | $940 | $55 |
| Albuterol Sulfate Hfa | 12 | $543 | $45 |
| Hydrocodone-Acetaminophen | 25 | $339 | $14 |
| Amitriptyline | 24 | $254 | $11 |
| Gabapentin | 15 | $243 | $16 |
| Losartan | 11 | $225 | $20 |
| Atorvastatin | 28 | $162 | $6 |
| Levothyroxine | 11 | $123 | $11 |
| Trazodone | 27 | $122 | $5 |
| Fluticasone Propionate | 14 | $122 | $9 |
| Hydroxyzine Pamoate | 24 | $91 | $4 |
| Tamsulosin | 19 | $83 | $4 |
| Cyclobenzaprine | 18 | $82 | $5 |
| Metformin | 27 | $81 | $3 |
| Amlodipine Besylate | 21 | $53 | $3 |
| Metoprolol | 11 | $50 | $5 |
| Ibuprofen | 11 | $38 | $3 |
2019: 11 drugs
| Chlorthalidone | 14 | $648 | $46 |
| Oxybutynin Chloride | 11 | $488 | $44 |
| Levothyroxine | 26 | $470 | $18 |
| Gabapentin | 24 | $385 | $16 |
| Atorvastatin | 17 | $311 | $18 |
| Losartan | 16 | $243 | $15 |
| Amitriptyline | 14 | $157 | $11 |
| Metformin | 16 | $145 | $9 |
| Fluticasone Propionate | 12 | $145 | $12 |
| Lisinopril | 12 | $130 | $11 |
| Tramadol | 13 | $54 | $4 |
2018: 8 drugs
| Vesicare | 12 | $4,478 | $373 |
| Chlorthalidone | 12 | $640 | $53 |
| Gabapentin | 22 | $418 | $19 |
| Levothyroxine | 15 | $350 | $23 |
| Hydrocodone-Acetaminophen | 13 | $297 | $23 |
| Atorvastatin | 11 | $278 | $25 |
| Lisinopril | 21 | $202 | $10 |
| Hydrochlorothiazide | 13 | $63 | $5 |
2017: 4 drugs
| Atorvastatin | 13 | $280 | $22 |
| Levothyroxine | 12 | $188 | $16 |
| Alendronate | 14 | $127 | $9 |
| Lisinopril | 12 | $65 | $5 |
Money from drug and device companies
$266 in 2025
A payment is not proof that care is biased.
| Heartflow | Ffrct | $192 | 1 payment
|
| Kowa Pharmaceuticals America | Zoryve | $44 | 2 payments
|
| Astellas Pharma US | Veozah | $30 | 1 payment
|
See all 4 published payments
| Kowa Pharmaceuticals America | Meals · 2025-12-11 | Zoryve | $21 |
| Kowa Pharmaceuticals America | Meals · 2025-11-20 | Zoryve | $22 |
| Heartflow | Meals · 2025-10-23 | Ffrct | $192 |
| Astellas Pharma US | Meals · 2025-10-17 | Veozah | $30 |
Professional record
- NPI
- 1144675497
- Licence
- CA A160010California A160010: Current · expires 2028-12-31
- Trained
- Emory University School of Medicine, 2016
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Family medicine (207Q00000X); Federal specialty code 261QM2500X (261QM2500X)
- Mailing address
- 80 Clayton Ave, San Jose, CA, 95110
- NPI first listed
- 2016-04-24
- NPI last updated
- 2024-08-05
- NPI record certified
- 2024-08-05
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 69 Grove St, New Canaan, CT, 06840 · 148 E 38th St, New York, NY, 10016 · 500 W Main St Ste 16, Wyckoff, NJ, 07481